melatonin has been researched along with Glaucoma, Suspect in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects." | 9.34 | Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects. ( Bodas-Romero, J; Carracedo-Rodríguez, G; Martínez-Águila, A; Pintor, J; Rodriguez-Pomar, C; Sanchez-Naves, J, 2020) |
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 7.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 7.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| "In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma." | 7.79 | Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. ( Bergua, A; Fonseca, B; Martínez-Águila, A; Pintor, J, 2013) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 7.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| "Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss." | 5.72 | Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022) |
| "Melatonin treatment might be considered a new strategy for protecting retinal neurons against pyroptosis following acute HIOP injury." | 5.62 | Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension. ( Chen, D; Guo, L; Huang, J; Huang, Y; Tan, C; Xue, F; Zhang, Y; Zhao, M, 2021) |
| "To evaluate the effect of a new nutritional supplement based on melatonin on the intraocular pressure (IOP) in normotensive subjects." | 5.34 | Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects. ( Bodas-Romero, J; Carracedo-Rodríguez, G; Martínez-Águila, A; Pintor, J; Rodriguez-Pomar, C; Sanchez-Naves, J, 2020) |
| "To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma." | 3.85 | Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017) |
| "Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma." | 3.85 | [Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017) |
| "In the search for new compounds to reduce intraocular pressure (IOP), with fewer side effects, we have found that agomelatine, a melatonin analogue, can reduce IOP being, therefore, interesting for the treatment of ocular hypertension and glaucoma." | 3.79 | Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. ( Bergua, A; Fonseca, B; Martínez-Águila, A; Pintor, J, 2013) |
| "Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits." | 3.77 | Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011) |
| "Melatonin and its analogue, 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT), potently reduce intraocular pressure, and may be good candidates for the treatment of ocular hypertension and glaucoma." | 3.74 | Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT. ( Alarma-Estrany, P; Crooke, A; Peral, A; Pintor, J, 2007) |
| " Here we describe three experiments which investigated: (i) the effects of sleep in five groups of subjects: glaucoma, suspect glaucoma, young high-normal IOP, old high-normal IOP groups and an elderly control group, (ii) the effect of exposure to bright light (2500 lux) during sleep on associated IOP changes, and (iii) the relationship between changes in IOP and plasma melatonin during sleep." | 3.68 | Investigation of parameters influencing intraocular pressure increases during sleep. ( Brown, B; Eyeson-Annan, M; Fletcher, T; Swann, PG; Wildsoet, C, 1993) |
| "Glaucoma is a neurodegenerative pathology that affects the optic nerve producing blindness." | 2.45 | New treatments for ocular hypertension. ( Alarma-Estrany, P; Mediero, A; Pintor, J, 2009) |
| "Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss." | 1.72 | Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022) |
| "Melatonin treatment might be considered a new strategy for protecting retinal neurons against pyroptosis following acute HIOP injury." | 1.62 | Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension. ( Chen, D; Guo, L; Huang, J; Huang, Y; Tan, C; Xue, F; Zhang, Y; Zhao, M, 2021) |
| "Glaucoma is an optic neuropathy in which retinal ganglion cells die probably through an apoptotic process." | 1.32 | Retinal oxidative stress induced by high intraocular pressure. ( Campanelli, J; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, P; Sánez, DA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, D | 1 |
| Xu, Y | 1 |
| Shi, Y | 1 |
| Fan, M | 1 |
| Lu, P | 1 |
| Bai, X | 1 |
| Feng, Y | 1 |
| Hu, C | 1 |
| Cui, K | 1 |
| Tang, X | 1 |
| Liao, J | 1 |
| Huang, W | 1 |
| Xu, F | 1 |
| Liang, X | 1 |
| Huang, J | 2 |
| Carracedo-Rodríguez, G | 1 |
| Martínez-Águila, A | 3 |
| Rodriguez-Pomar, C | 1 |
| Bodas-Romero, J | 1 |
| Sanchez-Naves, J | 2 |
| Pintor, J | 7 |
| Zhang, Y | 2 |
| Huang, Y | 1 |
| Guo, L | 1 |
| Zhao, M | 1 |
| Xue, F | 1 |
| Tan, C | 1 |
| Chen, D | 1 |
| Pescosolido, N | 1 |
| Gatto, V | 1 |
| Stefanucci, A | 1 |
| Rusciano, D | 1 |
| Alkozi, H | 1 |
| de Lara, MJ | 1 |
| Carracedo, G | 1 |
| Fonseca, B | 2 |
| Chesnokova, NB | 1 |
| Beznos, OV | 1 |
| Lozinskaya, NA | 1 |
| Volkova, MS | 1 |
| Zaryanova, EV | 1 |
| Zefirov, NA | 1 |
| Grigoryev, AV | 1 |
| Alarma-Estrany, P | 4 |
| Crooke, A | 2 |
| Mediero, A | 2 |
| Peláez, T | 2 |
| Guzman-Aranguez, A | 1 |
| Huete, F | 1 |
| Peral, A | 2 |
| Plourde, R | 1 |
| Yerxa, B | 1 |
| Bergua, A | 1 |
| Moreno, MC | 1 |
| Campanelli, J | 1 |
| Sande, P | 1 |
| Sánez, DA | 1 |
| Keller Sarmiento, MI | 1 |
| Rosenstein, RE | 1 |
| Wildsoet, C | 1 |
| Eyeson-Annan, M | 1 |
| Brown, B | 1 |
| Swann, PG | 1 |
| Fletcher, T | 1 |
| Liu, JH | 1 |
| Shieh, BE | 1 |
1 review available for melatonin and Glaucoma, Suspect
| Article | Year |
|---|---|
New treatments for ocular hypertension.
Topics: Adrenergic Agents; Animals; Eye; Glaucoma; Humans; Melatonin; Neuropharmacology; Nucleotides; Ocular | 2009 |
1 trial available for melatonin and Glaucoma, Suspect
| Article | Year |
|---|---|
Effect of nutritional supplement based on melatonin on the intraocular pressure in normotensive subjects.
Topics: Adult; Antioxidants; Female; Follow-Up Studies; Healthy Volunteers; Humans; Intraocular Pressure; Ma | 2020 |
12 other studies available for melatonin and Glaucoma, Suspect
| Article | Year |
|---|---|
Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 8; DNA Nucleotidylexotransferase; | 2022 |
Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension.
Topics: Animals; Caspase 1; Interleukin-18; Intracellular Signaling Peptides and Proteins; Melatonin; NF-kap | 2021 |
Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients.
Topics: Acetamides; Administration, Oral; Aged; Antihypertensive Agents; Female; Glaucoma, Open-Angle; Human | 2015 |
Elevated intraocular pressure increases melatonin levels in the aqueous humour.
Topics: Adult; Aged; Aged, 80 and over; Animals; Aqueous Humor; Biomarkers; Chromatography, High Pressure Li | 2017 |
[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma].
Topics: Animals; Antioxidants; Drug Design; Gene Expression; Glaucoma; Indoles; Intraocular Pressure; Ligand | 2017 |
Sympathetic nervous system modulates the ocular hypotensive action of MT2-melatonin receptors in normotensive rabbits.
Topics: 1-Methyl-3-isobutylxanthine; Administration, Topical; Adrenergic beta-Agonists; Albuterol; Animals; | 2008 |
Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Eye; Glaucoma; Intraocular Pressure; Isoindo | 2011 |
Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions.
Topics: Acetamides; Animals; Dose-Response Relationship, Drug; Intraocular Pressure; Melatonin; Ocular Hyper | 2013 |
Retinal oxidative stress induced by high intraocular pressure.
Topics: Animals; Antioxidants; Free Radicals; Glaucoma; Glutathione; Hyaluronic Acid; Intraocular Pressure; | 2004 |
Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT.
Topics: Adrenergic Uptake Inhibitors; Animals; Central Nervous System Depressants; Dose-Response Relationshi | 2007 |
Investigation of parameters influencing intraocular pressure increases during sleep.
Topics: Adult; Age Factors; Aged; Female; Glaucoma; Humans; Intraocular Pressure; Light; Male; Melatonin; Mi | 1993 |
Suprachiasmatic nucleus in the neural circuitry for the circadian elevation of intraocular pressure in rabbits.
Topics: Animals; Aqueous Humor; Circadian Rhythm; Intraocular Pressure; Light; Male; Melatonin; Neural Pathw | 1995 |